---
title: "688062.SH (688062.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688062.SH/news.md"
symbol: "688062.SH"
name: "688062.SH"
parent: "https://longbridge.com/en/quote/688062.SH.md"
datetime: "2026-03-09T17:01:43.513Z"
locales:
  - [en](https://longbridge.com/en/quote/688062.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688062.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688062.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688062.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688062.SH/news.md)


# 688062.SH (688062.SH) — Related News

### [New Stock News | Mabwell's Hong Kong IPO Prospectus Invalid](https://longbridge.com/en/news/277399852.md)
*2026-03-02T03:50:04.000Z*
> Mabwell (Shanghai) Biotechnology Co., Ltd. (Mabwell) submitted its Hong Kong IPO prospectus on August 29, 2025, which ha

### [Mabwell: Expected net profit loss of 900 million to 994.5 million yuan in 2025](https://longbridge.com/en/news/273481683.md)
*2026-01-23T07:51:37.000Z*
> Mabwell announced that the company expects to continue to incur losses in 2025 compared to the same period last year, wi

### [Mabwell's targeted CDH17 ADC innovative drug 7MW4911 has completed the administration to the first patient in the U.S. clinical trial](https://longbridge.com/en/news/273204448.md)
*2026-01-21T09:18:02.000Z*
> Mabwell announced that the clinical trial of its targeted CDH17 ADC innovative drug for patients with advanced colorecta

### [Mabwell has reached a strategic cooperation with Sentonix](https://longbridge.com/en/news/271715175.md)
*2026-01-07T00:42:45.000Z*
> Mabwell announced the signing of a global strategic cooperation agreement with the emerging biotechnology company Senton

### [Mabwell's Adalimumab biosimilar "JUNMAIKANG" gets marketing approval in Indonesia. 9MW0113 is the injection.](https://longbridge.com/en/news/271224036.md)
*2025-12-31T14:02:14.000Z*
> On December 31, 2025, Mabwell, a biopharmaceutical company focused on innovation, revealed that its Adalimumab Injection

### [Mabwell doses first patient in Phase II anti-IL-11 antibody trial](https://longbridge.com/en/news/271205143.md)
*2025-12-31T10:47:19.000Z*
> Mabwell has initiated its Phase II clinical trial for the anti-IL-11 antibody (9MW3811) in China, marking the first glob

### [Mabwell: Adalimumab injection has been approved for marketing in Indonesia](https://longbridge.com/en/news/271163801.md)
*2025-12-31T02:39:42.000Z*
> On December 31, Mabwell announced that its adalimumab injection 9MW0113 has received registration approval from the Indo

### [Mabwell announces first patient dosed in phase II trial of anti-IL-11 antibody for pathological scarring](https://longbridge.com/en/news/271115369.md)
*2025-12-30T14:10:36.000Z*
> Mabwell announces first patient dosed in phase II trial of anti-IL-11 antibody for pathological scarring